Individual vulnerability to mood and stress disorders will be predictable

The dream of personalized medicine in mental health is to prevent disorders in people most at risk and to provide tailored treatment for those who do develop them. While not there yet, this is an achievable aim, and we know what the future will look like, Charles Nemeroff told APAAM 2021.

Artificial intelligence will combine information about an individual’s genotype, epigenetics  and metabolomics and integrate it with evidence of adverse experiences to predict vulnerability to anxiety, depression and post-traumatic stress disorder, Professor Nemeroff said during his lecture accepting the first annual Nasrallah Family Neuroscience Award.

The algorithms that result will predict both the likelihood of developing a disorder, and the chances that any given patient will respond to different approaches to treatment (such as pharmacotherapy versus cognitive behavior therapy) or even different agents within an approach, such as use of an SSRI or an SNRI.

Gene-environment interaction is the norm in determining vulnerabiity, and epigenetics has a major role

Given the capacity of machine learning to handle vast amounts of data, and our understanding of predictive factors – which range from childhood trauma to the presence of one or two short alleles in the serotonin transporter gene -- such a future can be foreseen, argued Professor Nemeroff (Dell Medical School, University of Texas Austin, USA). But we are not there yet.


Examples of what we do know

Several studies provide sound evidence of the interaction between genotype and environment in determining outcome:

  • Childhood abuse alters the endogenous stress response, which is orchestrated by corticotropin-releasing hormone (CRH). Polymorphisms in the CRH receptor type 1 gene strongly interact with level of childhood abuse to predict adult depression.1
  • This effect is similar to that seen previously in the archetypal study of gene-environment interaction showing that the probability of MDD following childhood maltreatment depends on a functional polymorphism in the promoter region of the serotonin transporter gene.2
  • Childhood abuse and adult trauma have additive effects on the severity of PTSD symptoms.3

We can also be certain of the pivotal part played by epigenetics. Around 98% of our genome is made up of non-coding DNA.4 While this does not code for proteins, it regulates gene expression through methylation.

Demethylation regulates the interaction between genes and trauma in determining risk of stress disorders5

We know, for example, that allele-specific demethylation regulates interactions between genes and childhood trauma. A polymorphism affecting the FK506 binding protein-5 gene increases the risk of stress-related disorders through demethylation and transcription.5 


And an example of what we don’t know

However, although sometimes promoted as ready for routine use, there is no consistent evidence for the benefit of commercially available tests for gene polymorphisms relevant to antidepressant metabolism, Professor Nemeroff noted.

A recent randomized, double-blind, multicenter trial involving 304 patients showed no significant improvement in MDD outcome when therapy guided by an assay for a panel of pharmacokinetic and pharmacodynamic variants was compared against treatment as usual.6 

A JAMA editorial noted that the use of pharmacogenomic tests to predict treatment efficacy in individual patients is a sincere and achievable goal, but we do not yet know how best to achieve it.7


For the latest updates on, subscribe to our Telegram Channel

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.


1. Bradley RG et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008; 65: 190-200

2. Caspi A et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301(5631):386-9 3. Binder RG et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008;299:1291-305 4. 5. Klengel T et al. Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions. Nature Neuroscience 2013; 16: 33–41 6. Perlis RH et al. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety 2020 ; 37:834-41 7. Zubenko GS et al. On the Marketing and Use of Pharmacogenetic Tests for Psychiatric Treatment. JAMA Psychiatry 2018 Aug 1;75(8):769-70
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country